2035, date not disclosed
Prevnar 20 expected to lose US exclusivity
Company guidance. Pfizer 10-K: US basic product patent expires 2035. Sales are the whole Prevnar family.
When does Prevnar 20 go off patent?
In the US, follow-on vaccines can launch from 2035. Prevnar 20 is sold by Pfizer. Pfizer 10-K: US basic product patent expires 2035. Sales are the whole Prevnar family.
Prevnar 20's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a vaccine. Vaccines are hard to copy, so competition after patents expire usually arrives slowly.
| Patent or protection | Covers | Expiry |
|---|---|---|
| US basic product patent | Prevnar 20 (Pfizer) | 2035 |
| FDA 12-year biologic exclusivity | Counted from approval on 8 June 2021 | 8 June 2033 |
| Europe and Japan basic product patents | Prevenar 20 | 2037 / 2038 |
Pfizer lists 2035 as the US expiry of Prevnar 20's basic product patent, with 2037 in Europe and 2038 in Japan. Vaccines are rarely copied; the competition comes from rival vaccines such as Merck's Capvaxive. Prevnar 13, the older vaccine, reaches its US basic patent expiry in 2026.
Sources: Pfizer 10-K 2025 · FDA Purple Book
| Year | Prevnar family (Prevnar 13 and 20), Pfizer | US | Growth |
|---|---|---|---|
| 2023 | $6.50B | – | – |
| 2024 | $6.41B | $4.23B | -1% |
| 2025 | $6.49B | $4.15B | +1% |
Net sales as reported, with the US share. Source: Pfizer 10-K 2025
No US filing found We found no US copy of Prevnar 20 in development. Its competition comes from rival vaccines such as Merck's Capvaxive, approved in 2024.
Checked October 2026. Sources: BioPharma Dive: Capvaxive approval
Prevnar 20 is 10% of Pfizer's 2025 revenue ($6.5B of $62.6B). With Ibrance, Xtandi, Eliquis and Vyndaqel, the drugs tracked here add up to 43% of Pfizer's revenue losing US exclusivity by 2035. Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Prevnar 20 is highlighted.
Company guidance. Pfizer 10-K: US basic product patent expires 2035. Sales are the whole Prevnar family.